CABAZITAXEL INJ,SOLN
Clinical Criteria Summary
Exclusion Criteria
- History of severe hypersensitivity reactions to drugs formulated with polysorbate 80
- Absolute Neutrophil Count (ANC) < 1500/mm3 or hemoglobin < 10 g/dL or platelets < 100,000/mm3
- Radiotherapy to 40% or more of bone marrow
- Hepatic impairment (bilirubin greater than 3x upper limit of normal)
- Active Grade 2 or higher peripheral neuropathy
- Inability or contraindication to taking prednisone
Inclusion Criteria
- Diagnosis of metastatic prostate cancer with documented disease progression during or after completion of docetaxel-based therapy
Additional Inclusion Criteria & Clinical Requirements
- Care is provided by a VA/VA Community Care oncology provider
- The goals of care and role of Palliative Care consult has been discussed and documented
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
- Prior and ongoing castrate levels of testosterone (less than 50 ng/dL) by either medical or surgical castration
- Patients with female partners of childbearing potential advised to use effective contraception during therapy and for 3 months following the last dose
Prophylaxis Considerations
- Consider primary prophylaxis with a Granulocyte-Colony Stimulating Factor (G-CSF) product for patients at high risk for neutropenia and those receiving a dose 25mg/m2